Patient Name : NIMISHA PACHAURY Collected : 02/Jun/2025 08:40AM
Age/Gender : 33 Years/F
UHID/MR No : LSHHI2132493 Reported : 02/Jun/2025 02:03PM
Visit ID : 192506020021 Status : Final Report
Ref By : Dr.DUNGAR SINGH GURJAR Panel Name : CGHS (CASH)
IP/OP NO : Barcode : HC10103723
DEPARTMENT OF CLINICAL BIOCHEMISTRY & IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval
IMMUNOGLOBULIN IgE, SERUM , Serum
IgE, Total 286.2 IU/mL 0.0 - 378.0
Chemiluminescence Immunoassay
Comment:
Elevated IgE concentrations can be found in patients with allergic diseases such as hay fever, atopic bronchitis and dermatitis. Normal
IgE values do not, however, mean that an allergic disease can be ruled out.
The quantitative determination of serum IgE concentrations is useful for clinical differentiation between atopic (i.e. Predisposition to
excessive IgE reaction) and non atopic (non–IgE mediated) allergic diseases only in combination with other clinical findings.
Elevated serum IgE concentration can also occur in non-allergic diseases eg. Congenital immunodeficiency syndromes, HIV infections,
severe burns and parasitic disease.
02-Jun-2025 02:37 PM Page 1 of 6
Processing Lab: SDA LAB Address: C-6/8, Safdarjung Development Area, Delhi-110016
Patient Name : NIMISHA PACHAURY Collected : 02/Jun/2025 08:40AM
Age/Gender : 33 Years/F
UHID/MR No : LSHHI2132493 Reported : 02/Jun/2025 02:27PM
Visit ID : 192506020021 Status : Final Report
Ref By : Dr.DUNGAR SINGH GURJAR Panel Name : CGHS (CASH)
IP/OP NO : Barcode : HC10103723
DEPARTMENT OF CLINICAL BIOCHEMISTRY & IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval
KIDNEY PANEL KFT BASIC , Serum
Urea 10.7 mg/dL 12.84 - 42.80
Calculated
Creatinine Serum 0.46 mg/dL 0.6 - 1.0
Modified Jaffe Kinetic
Uric Acid 3.65 mg/dL 2.6 - 6.0
Uricase/Peroxidase
Potassium 4.1 mEq/L 3.5 - 5.1
ISE Indirect
Sodium 137 mEq/L 136 - 145
ISE Indirect
Chloride 102 mEq/L 98 - 107
ISE Indirect
Blood Urea Nitrogen 5 mg/dL 6.0 - 20.0
Urease GLDH
Calcium, Total 8.8 mg/dL 9.0 - 10.1
O-cresolphthalein complexone
Comment:
As markers of renal function creatinine, urea, uric acid and electrolytes are for routine analysis.
Plasma urea or creatinine should be done as a guide to check the progression and disease prognosis if there is severe renal damage or obstruction.
Examination of urine is most important initial test for suspected renal damage, particularly glomerular diseases.
02-Jun-2025 02:37 PM Page 2 of 6
Processing Lab: SDA LAB Address: C-6/8, Safdarjung Development Area, Delhi-110016
Patient Name : NIMISHA PACHAURY Collected : 02/Jun/2025 08:40AM
Age/Gender : 33 Years/F
UHID/MR No : LSHHI2132493 Reported : 02/Jun/2025 02:27PM
Visit ID : 192506020021 Status : Final Report
Ref By : Dr.DUNGAR SINGH GURJAR Panel Name : CGHS (CASH)
IP/OP NO : Barcode : HC10103723
DEPARTMENT OF CLINICAL BIOCHEMISTRY & IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval
LIPID PROFILE, BASIC , Serum
Cholesterol Total 124 mg/dL < 200
CHO-POD
Triglycerides 149 mg/dL < 150
Enzymatic with glycerol Blank
HDL Cholesterol 66 mg/dL > 50
Direct enzymatic, calorimetric
VLDL Cholesterol 29.8 mg/dL < 30
Calculated
LDL/HDL Ratio 0.58 Ratio
Calculated
Total Cholesterol/HDL Cholesterol Ratio 1.88 Ratio
Calculated
LDL Cholesterol 38 mg/dL < 100
Direct measure
Comment:
NATIONAL LIPID ASSOCIATION RECOMMENDATIONS TOTAL CHOLESTERO in TRIGLYCERIDE in LDL CHOLESTEROL in
(NLA-2014) mg/dL mg/dL mg/dL
Optimal <200 <150 <100
Above Optimal - - 100- 129
Borderline High 200-239 150-199 130-159
High >=240 200-499 160-189
Very High - >=500 >=190
*Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol,
Triglycerides, HDL & LDL Cholesterol.
*Lipid Association of India (LAI) recommends screening of all adults above the age of 20 years for Atherosclerotic Cardiovascular Disease (ASCVD) risk
factors especially lipid profile. This should be done earlier if there is family history of premature heart disease, dyslipidemia, obesity or other risk factors.
*Indians tend to have higher triglyceride levels & Lower HDL cholesterol combined with small dense LDL particles, a pattern known as atherogenic
dyslipidemia.
* Non HDL Cholesterol comprises the cholesterol carried by all atherogenic particles, including LDL, IDL, VLDL & VLDL remnants, Chylomicron remnants &
Lp(a).
* LAI recommends LDL cholesterol as primary target and Non HDL cholesterol as co-primary treatment target 6. Apolipoprotein B is an optional, secondary
lipid target for treatment once LDL & Non HDL goals have been achieved.
*Additional testing for Apolipoprotein B, hsCRP, Lp(a ) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinemen.
Risk Stratification of ASCVD by Lipid Association of India 2016
02-Jun-2025 02:37 PM Page 3 of 6
Processing Lab: SDA LAB Address: C-6/8, Safdarjung Development Area, Delhi-110016
Patient Name : NIMISHA PACHAURY Collected : 02/Jun/2025 08:40AM
Age/Gender : 33 Years/F
UHID/MR No : LSHHI2132493 Reported : 02/Jun/2025 02:27PM
Visit ID : 192506020021 Status : Final Report
Ref By : Dr.DUNGAR SINGH GURJAR Panel Name : CGHS (CASH)
IP/OP NO : Barcode : HC10103723
DEPARTMENT OF CLINICAL BIOCHEMISTRY & IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval
Major ASCVD Risk Factors
1. Age >= 45 years in males and >= 55 years females.
2. Family h/o premature ASCVD(< 55 years of age in a male first degree relative or | | <65 years of age in a female first
degree relative).
3. Current Cigarette smoking or tobacco use.
4. High blood pressure.
5. Low HDL
ASCVD Risk Categories
Risk Non-Conventional Risk markers
Conventional Risk markers
Category (Optional)
1. Established ASCVD
Very High 2. Diabetes with 2 or more major ASCVD risk factors and/or evidence of end
None
Risk organ damage
3. Familial Homozygous hypercholesterolemia
1. >=3 major ASCVD risk factors
2. Diabetes with 0-1 major risk factor and no evidence of end organ damage.
1. Coronary artery calcium,CAC
3. CKD stage 3 B or 4
score >=300 AU.
High Risk 4. Familial Hypercholesterolemia( other than Familial Homozygous
2. Lp(a)> = 50 mg/dL
hypercholesterolemia).
3. Non stenotic carotid plaque
5. Extreme of a single factor e.g. LDL Cholesterol >190 mg/dL,Heavy
smoker, strong family h/o premature ASCVD.
1. Coronary artery calcium,CAC
Moderate score 100-299 AU.
Any 2 major ASCVD risk factors.
risk 2. Lp(a) 20-49 mg/dL.
3. Metabolic syndrome.
Low risk 0-1 major ASCVD risk factors None
Treatment Goals as per Lipid Association of India 2016
RISK CATEGORY CONSIDER THERAPY TREATMENT GOAL
LDL CHOLESTEROL (LDL-C)(mg/dL) LDL CHOLESTEROL (LDL-C)(mg/dL)
Very High >=50 <50
High >=70 <70
Moderate >=100 <100
Low >=130* <100
* In low risk patient, consider therapy after an initial non-pharmacological intervention for at least 3 months
02-Jun-2025 02:37 PM Page 4 of 6
Processing Lab: SDA LAB Address: C-6/8, Safdarjung Development Area, Delhi-110016
Patient Name : NIMISHA PACHAURY Collected : 02/Jun/2025 08:40AM
Age/Gender : 33 Years/F
UHID/MR No : LSHHI2132493 Reported : 02/Jun/2025 02:27PM
Visit ID : 192506020021 Status : Final Report
Ref By : Dr.DUNGAR SINGH GURJAR Panel Name : CGHS (CASH)
IP/OP NO : Barcode : HC10103723
DEPARTMENT OF CLINICAL BIOCHEMISTRY & IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval
LFT BASIC-LIVER PANEL BASIC , SERUM
Total Bilirubin 0.3 mg/dL 0.2 - 1.0
Diazotization
Conjugated Bilirubin 0.08 mg/dL 0.0 - 0.2
Diazotization
Indirect Bilirubin 0.22 mg/dL 0.2 - 1.0
Calculated
Total Protein 7.1 g/dL 6.4 - 8.2
Biuret
Albumin 3.1 g/dL 3.4 - 5.0
Bromocresol purple (BCP)
Globulin 4 g/dL 2.0 - 3.5
Calculated
A/G Ratio 0.78 Ratio >1
Calculated
SGPT (ALT) 39 U/L 7.0 - 35.0
IFCC with P5P
SGOT(AST) 21 U/L 18 - 34
IFCC with P5P
Alkaline Phosphatase 73 U/L 46 - 122
PNPP, AMP Buffer IFCC
Gamma Glutamyl Transferase 26 U/L 5 - 55
IFCC
Comment:
The clinical suspicion of liver disease usually leads to the measurement of the liver function tests (LFT) which include measurement of several enzymes, serum bilirubin and albumin. These
parameters may point to an underlying pathological process and direct further investigation.
The aims of investigation in patients with suspected liver disease are:
• To detect hepatic abnormality
• Measurement of severity of liver damage
• Identify the specific cause & Investigate possible complications
02-Jun-2025 02:37 PM Page 5 of 6
Processing Lab: SDA LAB Address: C-6/8, Safdarjung Development Area, Delhi-110016
Patient Name : NIMISHA PACHAURY Collected : 02/Jun/2025 08:40AM
Age/Gender : 33 Years/F
UHID/MR No : LSHHI2132493 Reported : 02/Jun/2025 02:03PM
Visit ID : 192506020021 Status : Final Report
Ref By : Dr.DUNGAR SINGH GURJAR Panel Name : CGHS (CASH)
IP/OP NO : Barcode : HC10103723
DEPARTMENT OF CLINICAL BIOCHEMISTRY & IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval
THYROID PROFILE, TOTAL ( T3,T4 & TSH) , Serum
T3 (Tri Iodothyronine) 1.65 ng/mL 0.60 - 1.81
CLIA
T4 (Thyroxine) 12.3 µg/dL 3.2 - 12.6
CLIA
TSH, ULTRASENSITIVE 2.257 µIU/mL 0.55 - 4.78
CLIA
Comment:
Age T3 Ref Range (ng/mL)
1st Trimester 0.80 - 1.90
2nd Trimesters 1.00 - 2.60
3rd Trimesters 1.00 - 2.60
Age TSH Ref Range (µIU/ mL)
1st Trimester 0.1 - 2.5
2nd Trimester 0.2 - 3.0
3rd Trimester 0.3 - 3.0
TSH levels are subjected to circadian variation, hence time of the day has influence on the measured serum TSH concentrations.
Total T3 and Total T4 levels are profoundly affected by altered concentration of thyroid binding protein espcially during pregnancy and
Patients on steroid therapy.
Unbound fraction of thyroid hormone is biologically active form and correlate more closely with clinical status of patient than Total
T3/Total T4 concentration.
*** End Of Report ***
Click here to Access Comparative Reports
Please Note: These comparative reports are based on your PatientID .
02-Jun-2025 02:37 PM Page 6 of 6
Processing Lab: SDA LAB Address: C-6/8, Safdarjung Development Area, Delhi-110016
